Your browser doesn't support javascript.
loading
Clonal hematopoiesis of indeterminate potential is rare in pediatric patients undergoing autologous stem cell transplantation.
Kartal-Kaess, Mutlu; Karow, Axel; Bacher, Ulrike; Pabst, Thomas; Joncourt, Raphael; Zweier, Christiane; Kuehni, Claudia E; Porret, Naomi Azur; Roessler, Jochen.
Affiliation
  • Kartal-Kaess M; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Inselspital, University Hospital, University of Bern, Bern, Switzerland.
  • Karow A; Department for BioMedical Research, University of Bern, Bern, Switzerland.
  • Bacher U; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Inselspital, University Hospital, University of Bern, Bern, Switzerland.
  • Pabst T; Department for BioMedical Research, University of Bern, Bern, Switzerland.
  • Joncourt R; Department of Pediatrics and Adolescent Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
  • Zweier C; Department for BioMedical Research, University of Bern, Bern, Switzerland.
  • Kuehni CE; Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Porret NA; Department for BioMedical Research, University of Bern, Bern, Switzerland.
  • Roessler J; Department of Medical Oncology, Inselspital, Bern University Hospital, Bern, University of Bern, Bern, Switzerland.
Pediatr Hematol Oncol ; : 1-10, 2024 Jun 06.
Article in En | MEDLINE | ID: mdl-38840569
ABSTRACT
Clonal hematopoiesis of indeterminate potential (CHIP) describes recurrent somatic gene mutations in the blood of healthy individuals, associated with higher risk for hematological malignancies and higher all-cause mortality by cardiovascular disease. CHIP increases with age and is more common in adult patients after chemotherapy or radiation for cancer. Furthermore, in some adult patients undergoing autologous stem cell transplantation (ASCT) or thereafter, CHIP has been identified. In children and adolescents, it remains unclear how cellular stressors such as cytotoxic therapy influence the incidence and expansion of CHIP. We conducted a retrospective study on 33 pediatric patients mostly with solid tumors undergoing ASCT for presence of CHIP. We analyzed CD34+ selected peripheral blood stem cell grafts after several cycles of chemotherapy, prior to cell infusion, by next-generation sequencing including 18 "CHIP-genes". Apart from a somatic variant in TP53 in one patient no other variants indicative of CHIP were identified. As a CHIP-unrelated finding, germline variants in CHEK2 and in ATM were identified in two and four patients, respectively. In conclusion, we could not detect "typical" CHIP variants in our cohort of pediatric cancer patients undergoing ASCT. However, more studies with larger patient numbers are necessary to assess if chemotherapy in the pediatric setting contributes to an increased CHIP incidence and at what time point.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Pediatr Hematol Oncol Journal subject: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Year: 2024 Document type: Article Affiliation country: Switzerland

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Pediatr Hematol Oncol Journal subject: HEMATOLOGIA / NEOPLASIAS / PEDIATRIA Year: 2024 Document type: Article Affiliation country: Switzerland